Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
One of the goals of psoriasis therapy is to achieve sustainable remission. Currently, genetically engineered biological drugs are most effective in the treatment of psoriasis. However, there is a certain proportion of patients with insufficient efficiency of genetic engineering biological therapy. O...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-08-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/3144 |
| _version_ | 1827961925190811648 |
|---|---|
| author | I. V. Rychkova O. A. Prytulo |
| author_facet | I. V. Rychkova O. A. Prytulo |
| author_sort | I. V. Rychkova |
| collection | DOAJ |
| description | One of the goals of psoriasis therapy is to achieve sustainable remission. Currently, genetically engineered biological drugs are most effective in the treatment of psoriasis. However, there is a certain proportion of patients with insufficient efficiency of genetic engineering biological therapy. One of the reasons for reducing the therapeutic response in patients with psoriasis may be the presence of metabolic syndrome.Objective: to study the therapeutic efficacy of ustekinumab in patients with psoriasis with metabolic syndrome.Materials and methods: 52 patients with plaque psoriasis receiving ustekinumab therapy were observed: 25/52 (48.0%) patients with metabolic syndrome, 27/52 (52.0%) - without metabolic syndrome. The proportion of patients who reached PASI75 by the 12th week among patients with psoriasis with and without metabolic syndrome was 17/25 (68.0%) and 23/27 (85.2%) (p>0.05), respectively; 24th week - 15/25 (60.0%) and 25/27 (92.6%) (p<0.05), respectively; 48th week-14/25 (56.0%) and 24/27 (88.9%) (p<0.05).Conclusion: therapeutic efficacy of ustekinumab is higher in patients with psoriasis without metabolic syndrome than in patients with metabolic syndrome. |
| first_indexed | 2024-04-09T16:34:32Z |
| format | Article |
| id | doaj.art-75cc20b7148c4195be78b25ac9f7fe71 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:32Z |
| publishDate | 2019-08-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-75cc20b7148c4195be78b25ac9f7fe712023-04-23T06:56:58ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-08-0101212813110.21518/2079-701X-2019-12-128-1313051Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disordersI. V. Rychkova0O. A. Prytulo1State Budgetary Healthcare Institution of the Republic of Crimea Clinical Dermatovenerologic DispensaryGeorgievsky Medical Academy, Federal State Autonomous Educational Institution of Higher Education Vernadsky Crimean Federal UniversityOne of the goals of psoriasis therapy is to achieve sustainable remission. Currently, genetically engineered biological drugs are most effective in the treatment of psoriasis. However, there is a certain proportion of patients with insufficient efficiency of genetic engineering biological therapy. One of the reasons for reducing the therapeutic response in patients with psoriasis may be the presence of metabolic syndrome.Objective: to study the therapeutic efficacy of ustekinumab in patients with psoriasis with metabolic syndrome.Materials and methods: 52 patients with plaque psoriasis receiving ustekinumab therapy were observed: 25/52 (48.0%) patients with metabolic syndrome, 27/52 (52.0%) - without metabolic syndrome. The proportion of patients who reached PASI75 by the 12th week among patients with psoriasis with and without metabolic syndrome was 17/25 (68.0%) and 23/27 (85.2%) (p>0.05), respectively; 24th week - 15/25 (60.0%) and 25/27 (92.6%) (p<0.05), respectively; 48th week-14/25 (56.0%) and 24/27 (88.9%) (p<0.05).Conclusion: therapeutic efficacy of ustekinumab is higher in patients with psoriasis without metabolic syndrome than in patients with metabolic syndrome.https://www.med-sovet.pro/jour/article/view/3144psoriasismetabolic syndrometherapeutic efficacyustekinumab |
| spellingShingle | I. V. Rychkova O. A. Prytulo Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders Медицинский совет psoriasis metabolic syndrome therapeutic efficacy ustekinumab |
| title | Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders |
| title_full | Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders |
| title_fullStr | Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders |
| title_full_unstemmed | Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders |
| title_short | Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders |
| title_sort | efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders |
| topic | psoriasis metabolic syndrome therapeutic efficacy ustekinumab |
| url | https://www.med-sovet.pro/jour/article/view/3144 |
| work_keys_str_mv | AT ivrychkova efficiencyustekinumabinthetreatmentofpatientswithpsoriasiswithmetabolicdisorders AT oaprytulo efficiencyustekinumabinthetreatmentofpatientswithpsoriasiswithmetabolicdisorders |